Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 4Recurrence 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 19fludarabine 18Cyclophosphamide 16Tacrolimus 12Whole-Body Irradiation 11Melphalan 11Mycophenolic Acid 10Bortezomib 9Busulfan 8trametinib 7Dexamethasone 7thymoglobulin 6Stem Cell Transplantation 6Lenalidomide 6Cyclosporine 6Sirolimus 5Nivolumab 5Methotrexate 5dabrafenib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Granulocyte Colony-Stimulating Factor 4Antilymphocyte Serum 4Alemtuzumab 4daratumumab 3aldesleukin 3Thiotepa 3Specimen Handling 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × 1-dodecylpyridoxal × Plasma cell × Clear all
NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
58 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡